Symposium1 July 1986Ethical and Financial Issues in Autologous Marrow Transplantation: A Symposium Sponsored by the University of Nebraska Medical CenterWILLIAM P. VAUGHAN, M.D., RUTH B. PURTILO, Ph.D., CARL D. BUTLER, B.B.A., JAMES O. ARMITAGE, M.D.WILLIAM P. VAUGHAN, M.D.Search for more papers by this author, RUTH B. PURTILO, Ph.D.Search for more papers by this author, CARL D. BUTLER, B.B.A.Search for more papers by this author, JAMES O. ARMITAGE, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-1-134 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptRapidly expanding interest in autologous marrow transplantation (AMT) as a supportive care technology that permits very-high-dose, curative-intent chemotherapy for malignancy has resulted in the definition of large numbers of patients as "eligible" for this form of therapy. Including only those patients with malignancies for which treatment strategies involving this technique already have shown a possibility of cure, and only patients less than 50 years of age, there may be as many as 40 000 patients per year in the United States who are candidates (1). At an average cost per patient of $100 000, the total cost to treat 40...References Other Papers Presented1. GALE R. Future applications of AMT. UCLA Medical Center, Los Angeles, California. Google Scholar2. PHILLIPS G. History and rationale for AMT. Cancer Center for British Columbia, Vancouver, British Columbia, Canada. Google Scholar3. ARMITAGE J. Applicatons of AMT—lymphoma. University of Nebraska College of Medicine, Omaha, Nebraska. Google Scholar4. SPITZER G. Application of AMT—solid tumors. M.D. Anderson Hospital and Tumor Institute, Houston, Texas. Google Scholar5. YEAGER A. Applications of AMT—leukemia. The Johns Hopkins Oncology Center, Baltimore, Maryland. Google Scholar6. BUTLER C. The database—what is the dollar cost? University of Nebraska Hospital, Omaha, Nebraska. Google Scholar7. BUCKNER C. Who's been paying the bill? Fred Hutchinson Cancer Center, Seattle, Washington. Google Scholar8. LIND S. Who should pay for the costs of therapeutic research? Massachusetts General Hospital, Boston, Massachusetts. Google Scholar9. CASSILETH B. When is research treatment the standard of care? University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania. Google Scholar10. SCHWEITZER S. Perspectives on medical care technology development and dissemination. UCLA School of Public Health, Los Angeles, California. Google Scholar11. BAKER R. The hospital perspective. University of Nebraska Hospital and Clinic, Omaha, Nebraska. Google Scholar12. OLDS R. The role of third parties. Mutual of Omaha, Omaha, Nebraska. Google Scholar13. WITTES R. The position of the clinical investigator. National Cancer Institute, Bethesda, Maryland. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: The University of Nebraska Medical Center Omaha, Nebraska PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByEthical Issues in Hematopoietic Cell TransplantationCost ConsiderationsThe True Cost of Bone Marrow TransplantationBone marrow transplantation: support of the patient and his/her familyPsychiatric and Psychosocial Aspects of Bone Marrow TransplantationPsychiatric aspects of bone marrow transplantation: Part I: Special issues during pre-transplant assessment and hospitalizationCost and Availability of TransplantationCost Effectiveness of Bone Marrow Transplantation in Acute Nonlymphocytic LeukemiaRapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy?Who Pays?DECISIONS OF JUSTICE AND HEALTH CARE 1 July 1986Volume 105, Issue 1Page: 134-135KeywordsBone marrowChemotherapyTransplantation Issue Published: 1 July 1986 PDF DownloadLoading ...